BDR Pharma Brings New Hope for Philadelphia Chromosome-Positive Leukemia Patients

On Wednesday, BDR Pharmaceuticals announced the launch of Nilotinib, a groundbreaking treatment for a rare subtype of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-positive (Ph+ ALL). By introducing Nilotinib, BDR Pharma aims to revolutionize the management of Ph+ leukemia and provide a game-changing solution for individuals battling this challenging form of cancer.

In India alone, over 70,000 new cancer cases are reported annually, with approximately 20,000 cases of leukemia, including 12,000-15,000 cases of acute lymphoblastic leukemia. Ph+ ALL, a rare childhood cancer subtype, accounts for 3-4% of pediatric cases and 25% of adult cases. Unfortunately, only 20% to 40% of adult acute lymphoblastic leukemia (ALL) patients in India are Ph+. Recognizing the need for an effective treatment option, BDR Pharmaceuticals developed Nilotinib, which has shown exceptional efficacy in achieving major molecular responses and significantly improving overall survival rates during clinical trials.

The introduction of Nilotinib is a testament to India's ongoing efforts in oncology healthcare, demonstrating a comprehensive approach to addressing the needs of patients.


Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks